Immuno-oncology Therapies

The development of immuno-oncology agents such as antibodies targeting the CTLA-4 and PD-1 protein receptors and the PD-L1 protein has demonstrated the importance of the human immune system in cancer therapy and the potential for high rates of more durable responses from agents that activate the immune system to identify and eliminate tumors. At BeiGene, we believe that combinations of immuno-oncology drugs and molecularly targeted therapies tailored to particular tumor types are the future of cancer treatment, and as such, have focused our research efforts on both types of drugs. Tislelizumab (BGB-A317), a PD-1 inhibitor, is the first drug candidate produced from our immuno-oncology biologic programs, and we think it could serve as a key element of our immuno-oncology combination platform.